Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants

An adjuvanted influenza vaccine for producing an antigenic response to influenza, in vivo, in mammals, said vaccine comprising:

• an effective amount of an influenza antigen and an adjuvant, said adjuvant comprising oil-containing paucilamellar lipid vesicles having nonphospholipid materials as the primary wall forming constituent, wherein said paucilamellar lipid vesicles have 2-10 bilayers surrounding an amorphous central cavity, and
• wherein said nonphospholipid materials are selected from the group consisting of polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, polyoxyethylene sorbitan esters, polyoxyethylene glyceryl mono- and diesters, glyceryl mono- and distearate, sucrose distearate, propylene glycol stearate, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, glyceryl mono-and diesters, dimethyl acyl amines, C12-C20 fatty alcohols, C12-C20 glycol monoesters, and C12-C20 fatty acids, and
• wherein said vaccine increases the antigenic response when compared to the antigen alone or the antigen adjuvanted with alum, wherein the antigen is mixed in solution with the adjuvant.